Roche: Tecentriq drug reduces melanoma death risk
(CercleFinance.com) - Roche said on Friday that its cancer immunotherapy Tecentriq plus targeted therapies helped to reduce the risk of disease worsening or death in patients with an aggressive form of skin cancer.
The Phase III study met its primary endpoint, showing a "significant and clinically" meaningful improvement in progression-free survival in people with previously untreated BRAF V600 mutation-positive advanced melanoma.
Roche has an extensive clinical trial development program for Tecentriq, with over 50 ongoing studies, including multiple Phase III studies across lung, kidney, skin, breast, prostate, ovarian, and blood cancers.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The Phase III study met its primary endpoint, showing a "significant and clinically" meaningful improvement in progression-free survival in people with previously untreated BRAF V600 mutation-positive advanced melanoma.
Roche has an extensive clinical trial development program for Tecentriq, with over 50 ongoing studies, including multiple Phase III studies across lung, kidney, skin, breast, prostate, ovarian, and blood cancers.
Copyright (c) 2019 CercleFinance.com. All rights reserved.